We empower oncologists to better treat cancer patients by unlocking a drug’s full potential through direct, sustained treatment at the tumor site.
While there have been tremendous advances in cancer treatment, critical challenges remain including limited ability of drugs to successfully reach the tumor, short half-life, and low retention rate on site. We have reimagined cancer therapies to tackle these long-standing challenges to successful treatment of the deadliest cancers.
Leveraging interventional oncology to design superior localized cancer treatments
- With the Sagittari™ platform, we engineer form factors that enable the direct targeting of drugs and other therapeutics precisely to the tumoral area.
- Bypassing the circulatory system reduces the off-target toxicities associated with traditional intravenous or oral administration of chemotherapy.
- Having a continuous prolonged source of drug in proximity of the tumor increases tissue retention and overcome short half-life.
Sagittari™ Platform
Our platform combines six interactive modules for optimal therapeutic design.
Sagittari™
Indication
We can target different indications, or types of cancers (e.g., pancreatic, colon, lung.)
Route of Administration
The route of administration we choose (e.g., minimally invasive, open surgery) depends on the location of the tumor we are targeting.
Form Factor
We can use form factors of varying shape and size (e.g., patch, tubular) to ensure the therapeutic reaches the target organ.
Therapeutic
The platform is compatible with different types of therapeutics, (e.g., molecules or monoclonal antibodies.)
Dose
We can change the amount of therapeutic that we introduce into the body, allowing for larger or smaller doses, as needed.
Timing
We can control how fast or slow the therapeutic agent is released into the body.
Pipeline
PanTher’s Sagittari™ platform is easily adaptable to pursue multiple solid tumor indications. Our vision is to build a robust portfolio of best-in-class therapeutics utilizing the versatility of our Sagittari™ technology.
| Discovery | Pre-clinical | IND-Enabling | Phase 1 | Phase 2 | Phase 3 | Approval | |
|---|---|---|---|---|---|---|---|
PTM-101Pancreas |
Phase 1 |
||||||
PTM-201Undisclosed |
IND-Enabling |
||||||
Undisclosed |
Discovery |
PTM-101
Our lead investigational candidate, PTM-101, is being evaluated for the treatment of pancreatic cancer. PTM-101 is a drug-eluting bifunctional film that utilizes an already FDA-approved biodegradable polymer and chemotherapeutic agent. PanTher designed PTM-101 to be administered via minimally invasive laparoscopic implantation.
PTM-101
Our lead investigational candidate, PTM-101, is being evaluated for the treatment of pancreatic cancer. PTM-101 is a drug-eluting bifunctional film that utilizes an already FDA-approved biodegradable polymer and chemotherapeutic agent. PanTher designed PTM-101 to be administered via minimally invasive laparoscopic implantation.
In pre-clinical research, PTM-101 has demonstrated a proven ability to effectively target chemotherapeutic drug accumulation providing the following advantages over standard systemic administration:
- Drastically enhanced local drug retention
- Absence of drug in the blood and other organs (e.g., liver)
- Improved efficacy
- Integration into standard laparoscopic procedures with no significant impact on procedure time
PTM-101 is currently being investigated in a Phase 1 trial as first line treatment for patients with localized inoperable pancreatic cancer.